NCT01882868 - A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions

Colorectal Cancer Metastatic

Interventions

DRUG

Aflibercept

Pharmaceutical form: Concentrated solution (100 mg/4 mL \[25 mg/mL\], 200 mg/8 mL \[25 mg/mL\]) for infusion; Route of administration: Intravenous

DRUG

Levofolinate

Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous

DRUG

Irinotecan

Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous

DRUG

5-FU

Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous

Trial Locations (19)

Investigational Site Number 392011, Chiba

Investigational Site Number 392018, Chūōku

Investigational Site Number 392016, Fukuoka

Investigational Site Number 392017, Fukuoka

Investigational Site Number 392001, Kashiwa-Shi

Investigational Site Number 392019, Kawasaki-Shi

Investigational Site Number 392015, Matsuyama

Investigational Site Number 392013, Mitaka-Shi

Investigational Site Number 392004, Nagoya

Investigational Site Number 392006, Osaka

Investigational Site Number 392014, Sagamihara-Shi

Investigational Site Number 392008, Sapporo

Investigational Site Number 392003, Sendai

Investigational Site Number 392009, Shimotsuke-Shi

Investigational Site Number 392012, Shinjuku-Ku

Investigational Site Number 392005, Suita-Shi

Investigational Site Number 392002, Sunto-Gun

Investigational Site Number 392010, Tsukuba

Investigational Site Number 392007, Yufu-Shi